ARTICLE | Clinical News
Pfizer launches U.S.’s first biosimilar epoetin
November 16, 2018 5:37 PM UTC
Pfizer Inc. (NYSE:PFE) launched the first biosimilar of anemia drug epoetin alfa in the U.S., priced at a 33.5% discount to the lowest priced reference product. Amgen Inc. (NASDAQ:AMGN) markets reference drug Epogen and Johnson & Johnson (NYSE:JNJ) markets Procrit.
Pfizer set Retacrit's wholesale acquisition cost (WAC) at $11.03 per 1,000 units/mL. That WAC is 57.1% below Procrit's WAC of $25.72 and 33.5% below the Epogen's $16.58 WAC...
BCIQ Company Profiles
BCIQ Target Profiles